C Lim1, M S Tsao2, L W Le3, F A Shepherd1, R Feld1, R L Burkes4, G Liu1, S Kamel-Reid5, D Hwang2, J Tanguay2, G da Cunha Santos2, N B Leighl6. 1. Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto. 2. Laboratory Medicine Program, University Health Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto. 3. Department of Biostatistics, Princess Margaret Cancer Centre, Toronto. 4. Division of Medical Oncology, Mount Sinai Hospital, Toronto. 5. Laboratory Medicine Program, University Health Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto Molecular Diagnostics Laboratory, University Health Network, Toronto, Canada. 6. Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto natasha.leighl@uhn.ca.
Abstract
BACKGROUND: Testing for EGFR mutations and ALK rearrangement has become standard in managing advanced nonsmall-cell lung cancer (NSCLC). However, many institutions in Europe, North America and other world regions continue to face a common challenge of facilitating timely molecular testing with rapid result turnaround time. We assessed the prevalence of biomarker testing for advanced NSCLC patients and whether testing affected the timeliness of treatment decisions. METHODS: We conducted a retrospective chart review of a random sample of one-quarter of all patients with advanced NSCLC referred to the Princess Margaret Cancer Centre from 1 April 2010 to 31 March 2013. RESULTS: Of 300 patients reviewed, 175 seen by medical oncology had nonsquamous NSCLC, 72% of whom had biomarker testing carried out. Patients tested for biomarkers were more likely to be female (47% versus 21%, P = 0.002), Asian (27% versus 6%, P = 0.005) and never smokers (42% versus 8%, P < 0.0001). Only 21% of patients with biomarker testing had results available at their initial oncology consultation. This group had a shorter median time from consultation to treatment decision (0 versus 22 days, P = 0.0008) and time to treatment start (16 versus 29, P = 0.004). Thirteen percent underwent repeat biopsy for molecular testing after the initial consultation. Of those with positive EGFR or ALK results, 19% started chemotherapy before biomarker results became available. CONCLUSIONS: Awaiting biomarker testing results can delay treatment decisions and treatment initiation for patients with advanced NSCLC. This may be avoided by incorporating reflex biomarker testing into diagnostic algorithms for NSCLC at the level of the pathologist, and further education of specialists involved in obtaining diagnostic cancer specimens to ensure they are sufficient for molecular testing.
RCT Entities:
BACKGROUND: Testing for EGFR mutations and ALK rearrangement has become standard in managing advanced nonsmall-cell lung cancer (NSCLC). However, many institutions in Europe, North America and other world regions continue to face a common challenge of facilitating timely molecular testing with rapid result turnaround time. We assessed the prevalence of biomarker testing for advanced NSCLCpatients and whether testing affected the timeliness of treatment decisions. METHODS: We conducted a retrospective chart review of a random sample of one-quarter of all patients with advanced NSCLC referred to the Princess Margaret Cancer Centre from 1 April 2010 to 31 March 2013. RESULTS: Of 300 patients reviewed, 175 seen by medical oncology had nonsquamous NSCLC, 72% of whom had biomarker testing carried out. Patients tested for biomarkers were more likely to be female (47% versus 21%, P = 0.002), Asian (27% versus 6%, P = 0.005) and never smokers (42% versus 8%, P < 0.0001). Only 21% of patients with biomarker testing had results available at their initial oncology consultation. This group had a shorter median time from consultation to treatment decision (0 versus 22 days, P = 0.0008) and time to treatment start (16 versus 29, P = 0.004). Thirteen percent underwent repeat biopsy for molecular testing after the initial consultation. Of those with positive EGFR or ALK results, 19% started chemotherapy before biomarker results became available. CONCLUSIONS: Awaiting biomarker testing results can delay treatment decisions and treatment initiation for patients with advanced NSCLC. This may be avoided by incorporating reflex biomarker testing into diagnostic algorithms for NSCLC at the level of the pathologist, and further education of specialists involved in obtaining diagnostic cancer specimens to ensure they are sufficient for molecular testing.
Authors: Lee S Schwartzberg; Hidehito Horinouchi; David Chan; Sara Chernilo; Michaela L Tsai; Dolores Isla; Carles Escriu; John P Bennett; Kim Clark-Langone; Christer Svedman; Pascale Tomasini Journal: NPJ Precis Oncol Date: 2020-06-24
Authors: C Lim; H S Sekhon; J C Cutz; D M Hwang; S Kamel-Reid; R F Carter; G da Cunha Santos; T Waddell; M Binnie; M Patel; N Paul; T Chung; A Brade; R El-Maraghi; C Sit; M S Tsao; N B Leighl Journal: Curr Oncol Date: 2017-04-27 Impact factor: 3.677
Authors: P K Cheema; S Raphael; R El-Maraghi; J Li; R McClure; L Zibdawi; A Chan; J C Victor; A Dolley; A Dziarmaga Journal: Curr Oncol Date: 2017-02-27 Impact factor: 3.677
Authors: David E Gerber; Mark A Socinski; Joel W Neal; Heather A Wakelee; Keisuke Shirai; Lecia V Sequist; Rachel P Rosovsky; Rogerio C Lilenbaum; Bruno R Bastos; Chao Huang; Melissa L Johnson; Paul J Hesketh; Deepa S Subramaniam; Martin F Dietrich; Feng Chai; Yunxia Wang; Julia Kazakin; Brian Schwartz; Joan H Schiller; Julie R Brahmer; Ronan J Kelly Journal: Lung Cancer Date: 2018-02-03 Impact factor: 5.705
Authors: Giulia Pasello; Giovanni Vicario; Fable Zustovich; Francesco Oniga; Stefania Gori; Francesco Rosetti; Andrea Bonetti; Adolfo Favaretto; Silvia Toso; Roberta Redelotti; Antonio Santo; Daniele Bernardi; Petros Giovanis; Cristina Oliani; Lorenzo Calvetti; Carlo Gatti; Giovanni Palazzolo; Zora Baretta; Alberto Bortolami; Laura Bonanno; Marco Basso; Jessica Menis; Donatella Da Corte; Stefano Frega; Valentina Guarneri; PierFranco Conte Journal: Oncologist Date: 2019-03-07
Authors: Heidi A Hamann; Elizabeth S Ver Hoeve; Lisa Carter-Harris; Jamie L Studts; Jamie S Ostroff Journal: J Thorac Oncol Date: 2018-05-23 Impact factor: 15.609
Authors: Nora S Sánchez; Michael P Kahle; Ann Marie Bailey; Chetna Wathoo; Kavitha Balaji; Mehmet Esat Demirhan; Dong Yang; Milind Javle; Ahmed Kaseb; Cathy Eng; Vivek Subbiah; Filip Janku; Victoria M Raymond; Richard B Lanman; Kenna R Mills Shaw; Funda Meric-Bernstam Journal: JCO Precis Oncol Date: 2019-09-24